Survival, functional outcomes and safety in patients with thymidine kinase 2 deficiency (TK2d) and an age of TK2d symptom onset ≤12 years who received pyrimidine nucleos(t)ide therapy

Important Information Related to Your Request:

The material below is provided in response to your specific search for information on UCBCOMPASS® and may contain information that is not part of the FDA-approved Prescribing Information. UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please review the Full Prescribing Information